Tuberculosis (BCG) vaccine 2027-2029 (2029-2030, 2030-2031)

The Ministry of Social Affairs and Health (later referred to as ”STM”) and the Finnish Institute for Health and Welfare (later referred to as "THL" or “Customer” ) request your tender for Tuberculosis (BCG) vaccine, required for vaccinating children under 7 years of age who belong to risk groups as part of the National Immunisation Program in Finland. The contract period is two (2) years during 2027-2029. The procurement contains two (2) one (1)-year contract period renewals (1 + 1) to extend the contract for the periods 2029-2030 and 2030-2031. Estimated quantity for the contract period including contract period renewals is 92,000 doses. Customer reserves the right to increase or decrease the ordered numbers of doses by up to 20%. The contract will be awarded to one Supplier based on a comparison of tenders. Tender that is economically the most advantageous will win the competition. The most economically advantageous Tender shall be a Tender with lowest price. Please note that all times given in the Call for Tender refer to local time in Finland. Call for Tenders, annexes: Annex 1 Contract Annex 2 JYSE 2025 SUPPLIES Annex 3 Delivery schedule Annex 4 Subcontractors Annex 5 Description of the Handi Service Annex 6 Bank details Annex 7 Quality Agreement

The purpose of the Ministry of Social Affairs and Health (STM) and the Customer is to procure Tuberculosis (BCG) vaccine for the risk group vaccinations in the National Immunisation Program in Finland. The tendered vaccine must be suitable for children under 7 years of age according to Article´s Summary of Product Characteristics (SPC). Pursuant to Section 2 of the Act on Public Procurement and Concession Contracts (Procurement Act), the contracting entity seeks to enhance efficiency in the use of public funds and to organise its procurement activities so that procurements can be carried out with optimal economy, quality and orderliness, taking advantage of existing competitive conditions and considering environmental and social aspects. These fundamental aims will be achieved by procuring one suitable vaccine for the National Immunisation Program. According to the Communicable Diseases Act (1227/2016), the Finnish Institute for Health and Welfare is obliged to supervise the implementation of the National Immunisation Program and other general vaccinations, and to monitor the implementation and impact of these vaccinations. For practical and effective implementation and supervision of the National Immunisation Program, it is appropriate to procure one suitable vaccine. Therefore, the procurement is not divided into lots. More information about National Immunisation Program and vaccinations can be found on the website of the Finnish Institute for Health and Welfare: https://thl.fi/aiheet/infektiotaudit-ja-rokotukset/rokotteet-a-o/bcg-eli-tuberkuloosirokote. The Customer will implement the procurement on behalf of STM. The roles of STM and Customer are described in more detail in section "Presentation of the contracting authority". The subject of procurement and the mandatory requirements relating to it are described in detail in this Call for Tender and its annexes. The contract will be awarded to one Supplier based on a comparison of tenders. If the Supplier has modified vaccine available/releases a modified vaccine during the contract period, the Parties may agree to substitute the Article with the modified vaccine. In case of substitution, all terms and prices in the Contract shall apply without modification. (Followed by General Terms of Public Procurements in Supply Contracts, Section 4.7) CONTRACT PERIOD The Contract shall enter into a force once the competent signatories of both the Contracting Parties have duly signed the Contract. The Contract shall expire when all contractual duties and obligations have been performed by both Parties. However, the contract period shall be counted from the first day of the month on which the Supplier has handed over the first delivery of the Articles to the Customer´s pharmaceutical wholesaler. The Contract period is two (2) years from the date defined previously above and the estimated quantity to be purchased for this period is 46,000 +/- 20% doses. After the contract period, the Customer reserves the right for the contract period renewals described in section "Description of renewals". Tenders will be compared in the manner described in section "Grounds for decision" of the Call for Tenders.